Prasco, Sunovion enter agreement over Xopenex authorized generic

Drug had sales of $474 million between June 2011 and June 2012

CINCINNATI, Ohio — Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

Prasco said Monday that it had entered an agreement with Sunovion Pharmaceuticals to distribute an authorized generic version of Sunovion's Xopenex (levalbuterol hydrochloride) inhalation solution in the 1.25-mg/3-mL, 0.63-mg/3-mL and 0.31-mg/3-mL strengths. An authorized generic is a branded drug marketed under its generic name at a reduced price, usually under a partnership between the branded drug's manufacturer and a third-party company.

Xopenex is used to treat and prevent bronchospasm in patients ages 6 years and older with reversible obstructive airway disease. Xopenex had sales of about $474 million during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.